Incubate and DLA Piper invite you to join us on the morning of Sunday, January 7th, as part of JPM Week 2024.
Incubate advocates for the patient, corporate, and investment communities by educating policymakers on the role of venture capital in bringing promising, innovative treatments to patients in need.
What We Do
Help ensure a level global playing field for investment and promote policies that empower life science innovators to build and grow in the United States.
Strengthen and protect U.S. intellectual property provisions by promoting patent and regulatory systems that encourage life sciences innovation.
Amplify the results
Spotlight the venture capital-driven breakthroughs that are transforming medicine for patients and health professionals around the globe.
Incubate Executive Director John Stanford sat down this week with Mary R. Grealy, CEO of the Healthcare Leadership Council, to discuss the latest developments in health policy on the Making Medicine podcast.
Fitch Ratings recently released an analysis showing that Medicare’s drug price negotiation program is expected to deter investments into small molecule drugs.
In late August, the Centers for Medicare & Medicaid Services announced the first 10 drugs that will be subject to Medicare price setting under last year’s Inflation Reduction Act.
Stories from the Early-Stage Life Sciences Ecosystem
Listen to industry experts delve into the process behind scientific breakthroughs (and how many of them almost never happened), where the life science ecosystem is taking us next, and most importantly, what it means for patients.